M. Subapanditha

发表

Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.

J. Moffat, K. Brown, J. Nilvebrant, 2018, Cancer research.

Wnt activation as a therapeutic strategy in medulloblastoma

Gary D Bader, Trevor J Pugh, B. Doble, 2020, Nature Communications.

Therapeutic targeting of the pre-metastatic stage in human lung-to-brain metastasis Running Title : Targeting of Pre-metastasis

I. Jurisica, T. Tokár, Mohini Singh, 2018 .

Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis.

I. Jurisica, T. Tokár, Mohini Singh, 2018, Cancer research.

BMI1 is a therapeutic target in recurrent medulloblastoma

B. Doble, Yoon-Jae Cho, H. Farooq, 2018, Oncogene.

Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells

B. Doble, Mohini Singh, C. Venugopal, 2015, Clinical Cancer Research.

Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors

S. C. Chafe, J. Moffat, C. Venugopal, 2022, Frontiers in Immunology.

Differentiation of Brain Tumor Initiating Cells.

C. Venugopal, Sheila K Singh, M. Kameda-Smith, 2018, Methods in molecular biology.

Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma

Gene W. Yeo, J. Moffat, J. Reimand, 2022, Nature Communications.

The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma.

J. Moffat, E. Ford, Mohini Singh, 2020, Cell stem cell.

Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma

J. Moffat, K. Brown, C. Venugopal, 2021, bioRxiv.

Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma

Trevor J Pugh, J. Moffat, T. Pugh, 2022, bioRxiv.

Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma

Gene W. Yeo, J. Moffat, J. Reimand, 2022, Nature Communications.

Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells

Gary D Bader, J. Moffat, Ruth Isserlin, 2019, Journal of Neuro-Oncology.

Flow-Cytometric Identification and Characterization of Neural Brain Tumor-Initiating Cells for Pathophysiological Study and Biomedical Applications

C. Venugopal, N. McFarlane, S. Mahendram, 2015 .

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment

J. Moffat, T. Kislinger, C. Venugopal, 2022, Journal for ImmunoTherapy of Cancer.

TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stem–Like Cells in a Redox-Sensitive Manner

P. Marcato, C. Giacomantonio, T. Sharif, 2018, Clinical Cancer Research.

Flow Cytometric Analysis of Brain Tumor Stem Cells.

C. Venugopal, Sheila K. Singh, M. Subapanditha, 2018, Methods in molecular biology.

Pyrvinium Targets CD 133 in Human Glioblastoma Brain Tumor – Initiating Cells

B. Doble, Mohini Singh, C. Venugopal, 2015 .

Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence

Gary D. Bader, Mohini Singh, C. Venugopal, 2021, Science advances.

A novel stem cell culture model of recurrent glioblastoma

C. Venugopal, N. McFarlane, P. Vora, 2015, Journal of Neuro-Oncology.

A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells

J. Moffat, B. Doble, C. Venugopal, 2019, Oncogene.

Detecting single cell interferon-beta production using a fluorescent reporter telomerase-immortalized human fibroblast cell line

K. Mossman, M. Subapanditha, David N. Hare, 2021, STAR Protocols.

An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma

C. Venugopal, D. Bakhshinyan, D. Uehling, 2023, Journal of Neuro-Oncology.